William Blair Investment Management LLC acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,274 shares of the biopharmaceutical company’s stock, valued at approximately $950,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP boosted its position in shares of Royalty Pharma by 5.1% during the third quarter. Allworth Financial LP now owns 7,837 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 381 shares during the period. R Squared Ltd bought a new position in shares of Royalty Pharma during the third quarter valued at approximately $233,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in shares of Royalty Pharma in the third quarter worth approximately $63,000. Maryland State Retirement & Pension System raised its holdings in shares of Royalty Pharma by 15.0% in the third quarter. Maryland State Retirement & Pension System now owns 26,428 shares of the biopharmaceutical company’s stock worth $1,542,000 after buying an additional 3,449 shares during the period. Finally, Ritholtz Wealth Management raised its holdings in shares of Royalty Pharma by 5.7% in the third quarter. Ritholtz Wealth Management now owns 4,955 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 268 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.
Royalty Pharma Price Performance
Royalty Pharma stock opened at $68.53 on Tuesday. The stock has a market cap of $39.40 billion, a price-to-earnings ratio of 57.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29. Royalty Pharma PLC has a 1 year low of $37.31 and a 1 year high of $70.37. The firm has a 50-day moving average of $61.61 and a two-hundred day moving average of $54.67.
Royalty Pharma Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $0.2350 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma’s payout ratio is currently 78.33%.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on RPRX shares. The Goldman Sachs Group reissued a “buy” rating and set a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Morgan Stanley upped their price objective on Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded Royalty Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 11th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $63.29.
View Our Latest Analysis on Royalty Pharma
Insider Activity at Royalty Pharma
In related news, EVP Marshall Urist sold 4,126 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the transaction, the executive vice president directly owned 270,401 shares in the company, valued at approximately $15,826,570.53. This trade represents a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,252 shares of company stock valued at $6,327,407 in the last ninety days. Insiders own 18.84% of the company’s stock.
Royalty Pharma Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
See Also
- Five stocks we like better than Royalty Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
